Drug Trial Radar · NCT07280377
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
Oct 27, 2021
Primary completion
Jul 30, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Oncolytics BiotechIndustry
- Sponsor type
- Industry
- Collaborators
- Crolll Gmbh; AIO-Studien-gGmbH
- First posted
- Dec 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate \[ORR; Cohorts 1,2, 4,and 5\] and disease control rate \[DCR; Cohort 3\]) in patients with advanced or metastatic gastrointestinal (GI) tumors. Cohorts 1-4 are not randomized; however, Cohort 5 is comprised of two treatment arms to which patients are randomized in a 1:1 ratio.
Conditions
- Anal Cancer Metastatic
- Squamous Cell Carcinoma of the Anus Stage Unspecified
- Pancreatic Cancer Metastatic
- Unresectable Pancreatic Carcinoma
Interventions
PelareorepDrug
Pelareorep 4.5 x 10\^10 TCID50 via 1-hour IV infusion
AtezolizumabDrug
Atezolizumab 840 mg IV infusion
Gemcitabine and nab-paclitaxelDrug
Gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2)
Trifluridine TipiracilDrug
Trifluridine/tipiracil administered at a 35 mg/m2 dose orally twice daily
mFOLFIRINOX Treatment RegimenDrug
mFOLFIRINOX- IV oxaliplatin 85 mg/m2; IV leucovorin 400 mg/m2; IV irinotecan 150 mg/m2; 5-FU 2400 mg/m2 by 46-hour infusion, per local standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5Time frame: At week 16 (within each cohort)
- Disease Control Rate (DCR) - Cohort 3Time frame: at week 16
- Overall Survival (OS) - Cohort 5Time frame: Cohort 5: From the date of randomization through long term follow up at 2 years
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Nationales Centrum für Tumorerkrankungen Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
SLK-Kliniken Heilbronn GmbH
Heilbronn, Baden-Wurttemberg, Germany
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
Gemeinschaftspraxis Dr. Med Bernhard Heinreich
Augsburg, Bavaria, Germany
Klinikum der Universität München
München, Bavaria, Germany
Hämatologisch-Onkologische Praxis Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, Germany
Asklepios Kliniken Hamburg GmbH
Hamburg, Free and Hanseatic City of Hamburg, Germany
Krankenhaus Nordwest
Frankfurt am Main, Hesse, Germany
St. Josef-Hospìtal, Bochum
Bochum, North Rhine-Westphalia, Germany
Universitätsmedizin Mainz
Mainz, Rhineland-Palatinate, Germany
Caritasklinikum Saarbrücken St. Theresia
Saarbrücken, Saarland, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, Germany
Universität Leipzig
Leipzig, Saxony, Germany
Charité Universitätsklinikum Berlin
Berlin, State of Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.